-
公开(公告)号:US20210355188A1
公开(公告)日:2021-11-18
申请号:US16624853
申请日:2018-06-19
申请人: IMMUNOCORE LIMITED
发明人: Philip William ADDIS , Nicole Joy BEDKE , Lucie BOUARD , Stephen HARPER , Nathaniel LIDDY , Tara MAHON , Ronan Pádraic O'DWYER
摘要: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
-
公开(公告)号:US20230416335A1
公开(公告)日:2023-12-28
申请号:US18324425
申请日:2023-05-26
申请人: Immunocore Limited
发明人: Philip William ADDIS , Nicole Joy BEDKE , Lucie BOUARD , Stephen HARPER , Nathaniel LIDDY , Tara MAHON , Ronan Pádraic O'DWYER
CPC分类号: C07K14/7051 , A61K47/6849 , A61P35/00 , A61K35/17 , A61K45/06 , C07K16/2809 , A61K38/00
摘要: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
-
公开(公告)号:US20220177541A1
公开(公告)日:2022-06-09
申请号:US17552300
申请日:2021-12-15
申请人: IMMUNOCORE LIMITED
发明人: Philip William ADDIS , Nicole Joy BEDKE , Lucie BOUARD , Stephen HARPER , Nathaniel LIDDY , Tara MAHON , Ronan Pádraic O'DWYER
摘要: The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL (SEQ ID NO: 1) derived from the germline cancer antigen PRAME. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native PRAME TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
-
-